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ABSTRACT
The use of iodinated contrast media is contraindicated in some 
patients due to serious life-threatening adverse events. In such 
cases, there are reports that gadolinium (gadobutrol), which is 
commonly employed in magnetic resonance imaging, may be 
used as contrast media for coronary angiography. We report 
two cases with a history of severe allergy to iodinated contrast 
agent who underwent coronary angiography with gadolinium. 
The procedures were well tolerated, the amount of contrast 
media did not exceed 0.3-0.4 ml/kg and the images obtained 
were of acceptable quality for diagnostic purposes.
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Case Report
RESuMO
Cinecoronariografia com Gadolínio em Pacientes  
com Alergia Grave ao Contraste Iodado
Em alguns pacientes a utilização dos meios de contraste ioda-
dos é contraindicada pela possibilidade de desencadearem 
efeitos colaterais graves ameaçadores da vida. Nesses casos, 
existem relatos em que o gadolínio (gadobutrol), comumente 
empregado na ressonância nuclear magnética, pode ser usado 
como meio de contraste para coronariografia. Relatamos dois 
casos com antecedente de alergia grave ao contraste iodado, 
que realizaram coronariografia com gadolínio. Os procedi-
mentos foram bem tolerados, a quantidade de contraste não 
excedeu 0,3 0,4 ml/kg e as imagens obtidas foram de qualidade 
aceitável para efeitos de diagnóstico.
DESCRITORES: Doença da artéria coronariana. Angiografia 
coronária. Meios de contraste. Gadolínio.
I odinated contrast agents are commonly used to perform coronary angiography and coronary angio-plasty, and are generally well tolerated. However, 
complications can occur; contrast nephropathy and 
allergic reactions are the most frequently reported. 
Most allergic reactions can be prevented by the prior 
use of corticosteroids and antihistamines. A gadoli-
nium-based contrast may be an option when there are 
contraindications for using iodinated contrasts due to 
severe allergic reactions.1
Most contrast agents used in magnetic resonance 
imaging (MRI) examinations are based on paramagnetic 
gadolinium ion chelates, which have been used since 
the late 1980s. In general, gadolinium-based contrast 
agents are considered to be much safer than iodinated 
agents. The gadolinium ion is quite toxic when circu-
lating freely, and it has a biological half-life of a few 
weeks, which is much higher than the approximately 
1.5-hour half-life of gadolinium chelate compounds. The 
gadolinium ion, when chelated to a molecule, has its 
pharmacokinetics altered, which accelerates its clearance 
and sharply decreases its toxicity. Gadolinium chelation 
allows for an increase of up to 500 times the rate of 
the renal excretion of the compound. The chelating 
agent is what differentiates the various gadolinium-based 
contrast media available in the market.2
The use of intra-arterial gadolinium-based contrast 
media is considered ‘off-label’, as it is indicated only 
for intravenous administration. Intra-arterial gadolinium 
use was first described by Pavone et al.3 in a study 
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of arterial portography in 12 patients with hepatic 
lesions. Since then, it has been used for peripheral 
and cerebral arteriography, coronary angiography, and 
coronary angioplasty in patients with severe reactions 
to iodinated contrast.1,2,4,5
The prevalence of allergic reactions to gadolinium 
is uncommon (0.07%), and higher in patients with his-
tories of allergic reactions to iodinated contrast agents.1,6 
The incidence of anaphylaxis ranges from 1/100,000 to 
1/500,000 administrations of gadolinium.
This study reports two cases of iodinated contrast 
agent substitution with gadolinium to perform coronary 
angiography in patients with contraindications to iodi-
nated contrast media due to severe allergic reactions.
CASE REPORTS
Case 1
Case 1 was a 63-year-old female patient with a 
history of dyspnea and chest pain (beginning three 
months prior) radiating to the left arm. The pain was 
related to ordinary activities, lasted three minutes, 
and improved with rest. The patient had experienced 
a previous myocardial infarction and had a history of 
angioedema and urticaria related to an examination 
with iodinated contrast. The patient’s blood pressure 
was 130/80  mmHg, and her heart rate was 62  bpm. 
Cardiopulmonary auscultation was normal.
The electrocardiogram at rest evidenced sinus rhythm 
and slow R wave progression at V1-V4. A transthoracic 
echocardiogram showed concentric left ventricular hy-
pertrophy and moderate left ventricular anteroapical wall 
hypocontractility. Dipyridamole myocardial scintigraphy 
presented pronounced transient hypo-uptake in the left 
ventricular anterior wall. A coronary angiography was 
then indicated.
Skin tests were performed with iodinated contrast 
media: the skin prick test with multiple dilutions, 
whose results were negative, and the intradermal test 
with pure substances, which showed positive results, 
contraindicating the procedure with iodinated contrast. 
The skin test was negative for gadolinium.
Three days prior to the coronary angiography, the 
patient was treated with 180  mg/day of fexofenadine 
orally and 20 mg of prednisone orally every eight hours, 
beginning the day before the examination.
A coronary angiography was performed via femoral 
artery access (5 F introducer and catheter); it revealed 
left circumflex and right coronary arteries lesions with 
no significant injury and 100% lesion of the middle 
third of the left anterior descending artery. Collateral 
circulation was present in the right coronary artery to 
the left anterior descending artery (+++/4+), and a left 
ventriculography was not performed. 34 mL of gadobutrol 
(Gadovist®, Bayer Schering Pharma – Berlin, Germany) 
were used, and the procedure was uneventful.
A coronary artery bypass graft (CABG) surgery was 
performed one week after the coronary angiography 
(anastomosis of the left internal thoracic artery left 
anterior descending artery (LAD). The patient had an 
uneventful recovery and was discharged on the tenth 
postoperative day.
Case 2
Case 2 was a 55-year-old female patient with a 
history of chest pain that radiated to the left arm at 
mild exertion, lasted 15 to 20 minutes, and improved 
with rest. She reported fibromyalgia and a history of 
allergy to iodinated contrast (anaphylactic shock), sulpha 
drugs, dipyrone, and non-steroidal anti-inflammatory 
drugs. The patient’s blood pressure was 120/80 mmHg, 
and her heart rate was 75  bpm. The cardiopulmonary 
auscultation was normal.
At rest, the electrocardiogram showed sinus 
rhythm with isolated ventricular extrasystoles and 
left ventricular overload. The transthoracic echocar-
diogram showed left ventricular ejection fraction of 
43%, systolic segment dysfunction (septal akinesia), 
and left ventricular relaxation alteration. A coronary 
angiography was then indicated.
Because of the history of anaphylaxis to iodinated 
contrast, no allergy tests for iodinated contrast agents were 
performed. The patient was treated prior to the coronary 
angiography with 180 mg/day of fexofenadine orally, 25 mg 
of hydroxyzine, and 20  mg of prednisone orally every 
eight hours, beginning 25 hours before the procedure.
A coronary angiography was performed via femoral 
artery access (5  F introducer and catheter); it showed 
coronary arteries with parietal irregularities. Left ven-
triculography was not performed. A total of 30  mL of 
gadobutrol was used, and the procedure was uneventful. 
The patient was discharged the next day.
DISCUSSION
This is the first publication in the English language 
regarding the use of gadobutrol in place of iodinated 
contrast for coronary angiography in patients with 
histories of severe allergies to iodine. Considering that 
severe life-threatening allergic reactions after using 
iodinated contrast are rare (1 death per 55,000 cases)7 
and that most patients respond satisfactorily to previous 
preparation with corticosteroid and antihistamine, it is 
difficult to find studies using gadolinium as a substitute 
for iodinated contrast in patients undergoing coronary 
angiography; publications are limited to case reports.
Since the clinical use of high doses of intra-arterial 
gadolinium has not been studied, it is prudent to restrict its 
use to 0.3 to 0.4 mmol/kg (equivalent to 0.3 to 0.4 mL/kg).2 
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Thus, tests performed with gadolinium should be care-
fully planned and use few views (adequately defining 
the coronary arteries), limit the number and volume of 
test injections, and forego the ventriculography.
The acute adverse reactions to intravenous gado-
linium use can be divided into major, severe, and 
minor; and between general and local. The overall 
incidence of adverse reactions to MRI contrast agents 
varies between approximately 2% and 4%. The 
most common general minor reactions are nausea, 
vomiting, rash, and headache, while common local 
reactions are irritation, burning sensations, and a 
feeling of cold. Cases of acute adverse reactions to 
gadolinium, such as laryngospasm and anaphylaxis, 
are rare.8 Adverse reactions after intravenous injec-
tion of gadolinium are more frequent in patients who 
have had previous reactions to any internal contrast 
use, either gadolinium or iodine contrast (twice the 
chance), and in patients with histories of asthma 
and allergies.9 
The effects of intra-arterial gadolinium use have been 
little studied, and most case reports in the literature do 
not mention any adverse reactions to gadolinium.1,3–5
The intracoronary injection of gadolinium can result 
in severe cardiac arrhythmia (ventricular fibrillation), 
which is caused by the osmolality (700  mOsm/kg) of 
the contrast injected directly into the coronary artery, 
more than twice the plasmatic osmolality.10 Another effect 
is nephrotoxicity, which may occur with high doses of 
gadolinium, although it is less nephrotoxic than the 
iodinated contrasts.1 Gadolinium should not be used in 
patients with chronic renal failure (estimated creatinine 
clearance < 30 mL/min/L, 1.73 m²) or in patients with 
acute renal failure of any severity due to the risk of 
developing nephrogenic systemic fibrosis.11 
The seriated control of creatinine (post-procedure) 
in the present cases showed no alterations, which in-
dicated that the doses used were safe.
The femoral technique was chosen due to the 
volume of gadolinium contrast, as the catheterisation 
of the coronary arteries using the femoral technique is 
usually easier to perform when compared to the radial 
access technique, and there is a decreased need for 
contrast tests to determine the location.
The major limitations to using gadolinium in an-
giography are the opacity, which is less than that of 
the iodinated contrast, and the maximum volume that 
can be used. In these cases, the images were of ac-
ceptable quality, clearly defining the coronary anatomy 
and the presence or absence of obstructive lesions 
(Figures 1 and 2).
Thus, it can be concluded that the gadolinium 
contrast medium is a potential alternative for patients 
with severe allergy to iodinated contrast media who 
require coronary angiography. 
Figure 1 – Case 1. A) Right coronary artery in the right anterior oblique 
view. B) Right coronary artery in the left anterior oblique view. C) Left 
coronary artery in the right anterior oblique cranial view and the left 
anterior descending artery with total obstruction in the middle third 
(arrow). D) Left coronary artery in the left anterior caudal oblique 
view. RCA = right coronary artery, LCA = left coronary artery, LAD = 
left anterior descending artery.
Figure 2 – Case 2. A) Left coronary artery in the right anterior oblique 
cranial view. B) Left coronary artery in the left anterior oblique caudal 
view. C) Right coronary artery in the cranial posteroanterior view. D) 
Right coronary artery in the left anterior oblique view. RCA = right 
coronary artery, LCA = left coronary artery.
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